I’ve found two more anti-CD40 agents. These have been tested in lupus nephritis (and other diseases). One is called toralizumab and the other is BG9588; I’ve seen riplizumab as a name, which would be bad as RIP means rest in peace. The other name was ruplizumab. Both target CD40 ligand. As there has been a safety signal for thromboembolism, all studies of both MABs have been stopped.
So I guess, we won't see anything on these two MABs concerning SLE or Rheumatoid arthritis.